Financings In Brief: ImmuLogic
Executive Summary
ImmuLogic: Registers with SEC for 2 mil. share common, secondary offering. Hambrecht & Quist, UBS Securities and Vector Securities International will manage the offering, and they have the option to purchase up to an additional 300,000 shares to cover over-allotments if there are any, the Waltham, Mass.-based allergy products firm notes. The company announced Aug. 24 that it had sold 1 mil. shares of common stock at $10 per share to Amerindo Investment Advisors in a public offering. Amerindo is a long-time investor in the company. With that offering, ImmuLogic had approximately 17.1 mil. shares outstanding and approximately $65 mil. in cash on hand...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth